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Abstract
Background: Cyclophosphamide, doxorubicin, vincristine, and prednisolone (CHOP) regimen includes a high dose
of prednisolone (100 mg/body), which exhibits an anticancer and antiemetic effect. However, its optimal use for
antiemetic therapy has not been established yet. We assessed the efficacy of granisetron plus aprepitant versus
granisetron for CHOP or rituximab-CHOP (R-CHOP) regimen-induced nausea and vomiting in malignant lymphoma.
Methods: This retrospective and observational clinical study included patients who received CHOP or R-CHOP
regimen as initiating chemotherapy between July 2010 and March 2016 (N = 39). Patients were assigned to an
aprepitant [aprepitant (125 mg on day 1, 80 mg on days 2–3) plus granisetron (3 mg); n = 15] or control regimen
group [granisetron (3 mg); n = 24]. Complete response (CR), defined as no vomiting and no use of rescue therapy
during overall phase (0–120 h), was the primary endpoint. Secondary endpoints included the time to first vomiting
and using rescue medication and complete protection (CP) defined as no vomiting and no retching and/or no
nausea and no rescue therapy. The patient records were investigated, and data were retrospectively analyzed.
Results: CR rate CP rates did not significantly differ between the groups during the observation period (80.0%
versus 83.3%, p = 1.000; and 80.0% versus 79.2%, p = 1.000, respectively). Additionally, the time to first vomiting and
using rescue medication in did not significantly differ between the groups (p = 0.909).
Conclusions: This study suggests that granisetron alone could be one treatment option in the management of
CINV in patients with non-Hodgkin lymphoma receiving CHOP or R-CHOP regimen.
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Background
Chemotherapy-induced nausea and vomiting (CINV) is
one of the most severe adverse events associated with can-
cer chemotherapy, and often affects patients’ quality of life
[1, 2]. Thus, the management of CINV is crucial for suc-
cessful cancer chemotherapy. The incidence of CINV is
greatly influenced by the emetogenic potential of the
anticancer drug. Anticancer drugs and regimens are classi-
fied into the following four categories regarding the risk of
CINV: high (high-emetic chemotherapy: HEC) risk > 90%;
moderate (moderate-emetic chemotherapy: MEC) risk, 30
to 90%; low (low-emetic chemotherapy: LEC) risk, 10 to
30%; and minimal risk, < 10% [3].
The cyclophosphamide, doxorubicin, vincristine, and pred-
nisolone (CHOP) regimen is the standard chemotherapy for
primary aggressive non-Hodgkin lymphoma. This regimen
includes doxorubicin (50mg/m2), cyclophosphamide (750
mg/m2), vincristine (1.4mg/m2), and prednisolone (100mg/
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body). The R-CHOP regimen has been shown to signifi-
cantly extend overall survival compared with the CHOP regi-
men in patients with diffuse large B-cell lymphoma, and is
regarded as a standard therapy [4].
The National Comprehensive Cancer Network (NCCN),
American Society of Clinical Oncology (ASCO), and Japan
Society of Clinical Oncology antiemesis guidelines classify
the AC regimen (doxorubicin at 60mg/m2 and cyclophos-
phamide at 600mg/m2) as HEC, and recommend a com-
bination of 5-HT3 receptor antagonist, dexamethasone,
and NK1 receptor antagonist for HEC [5–7]. The CHOP
regimen has not been categorized according to the emeto-
genic risk in the ASCO, NCCN, or Multinational Associ-
ation of Supportive Care in Cancer/European Society of
Medical Oncology guidelines. It is unclear whether AC
used as a component of the CHOP regimen is also highly
emetic. On the other hand, the CHOP regimen has been
categorized HEC on the basis of consensus-based recom-
mendation in Japan Society of Clinical Oncology antiemesis
guidelines [5]. However, in a clinical setting, the aprepitant
tend to be not used as an antiemetic agent for the manage-
ment of CINV induced by CHOP regimen, because patients
are administered 100mg of prednisolone orally for 5 days,
which may decrease the risk of CINV. Actually, in a recent
observational study conducted in Japan, 79% of patients
with hematological malignancies who received HEC, in-
cluding CHOP regimen, did not used aprepitant [8].
Against this background, it is unknown whether NK1 re-
ceptor antagonists are necessary for the CHOP regimen.
Therefore, we assessed the efficacy of the combination of
granisetron and aprepitant for the management of CINV in
Japanese patients with non-Hodgkin lymphoma receiving
CHOP or R-CHOP regimen.
Methods
Patients
This study included patients who received CHOP or R-
CHOP regimen as initial chemotherapy between July 2010
and March 2016 at Shiga University of Medical Science
Hospital hematology (N = 39). The patients using aprepi-
tant and granisetron as antiemetic drugs were classified
into the aprepitant regimen group, whereas those using
only granisetron were classified into the control regimen
group. The exclusion criteria in this study included the
use of palonosetron, prophylactic administration of anti-
emetic drugs (dopamine-2 (D2) receptor antagonist) and
the use of methylprednisolone for the treatment of infu-
sion reaction induced by rituximab, not receiving doxo-
rubicin, cyclophosphamide or prednisolone.
Therapies
The CHOP regimen consisted of cyclophosphamide (750
mg/m2 intravenously), doxorubicin (50mg/m2 intraven-
ously), and vincristine (1.4mg/m2 intravenously), on day 1,
and prednisolone (100mg orally) on days 1–5. The day on
which the administration of the antiemetic drug was started
was set as day 1. In both groups, in the case of the CHOP
regimen, 3mg of granisetron was administered in 30min,
doxorubicin at 50mg/m2 was administered in 30min,
followed by vincristine at 1.4mg/m2 in 30min and cyclo-
phosphamide at 750mg/m2 in 2 h on day 1. Prednisolone
was administered at 100mg daily (55mg in the morning,
30mg in the afternoon 15mg in the evening) for 5 days
from day 1. In the case of the R-CHOP regimen, in addition
to administration of the CHOP regimen, rituximab was ad-
ministered on day 0. No additional administration of cor-
ticosteroid other than CHOP was performed as a
premedication of rituximab. The use of aprepitant was se-
lected at the discretion of the doctor, and 125mg was ad-
ministered 1 h before doxorubicin on day 1, and 80mg on
each of days 2 and 3, only to the aprepitant regimen group.
Assessments
The primary endpoints included proportions of patients
with complete response (CR; no vomiting and no use of
rescue therapy) in the acute phase (0–24 h), delayed
phase (24–120 h), and overall phase (0–120 h). The sec-
ondary endpoints included the proportion of patients
with complete protection (CP; no vomiting and no
retching and/or no nausea, no use of rescue therapy)
and time to first vomiting and using rescue medication.
Retrospective investigations were performed using elec-
tronic medical records. Retching/nausea or vomiting was
considered to have occurred if there was a description of
it in the electronic medical records. The evaluation
period was 120 h after the start of chemotherapy.
Statistics
Descriptive data are expressed as mean ± SD. The Man-
tel–Haenszel test was used to analyze the CR rate and
CP rate in the evaluation period. The Kaplan–Meier
method was used to estimate the time to first onset of
vomiting and using rescue medication. All comparison
tests were two-sided. p < 0.05 was considered to be sta-
tistically significant. The ethics committee of Shiga Uni-
versity of Medicine approved the protocol (approval
number: 28–27). This study is an observational retro-
spective analysis. Consequently, this study is not regis-
tered and does not have a trial registration number.
Results
Patient baseline clinical characteristics
In this study, 58 patients who were administered CHOP or
R-CHOP regimen were enrolled. Overall 19 patients were
excluded, for the following reasons: nine patients used palo-
nosetron, five had prophylactic administration of antiemetic
drugs in addition to granisetron, and five did not receive
doxorubicin, cyclophosphamide, or prednisolone. Overall,
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24 and 15 patients in the control and aprepitant regimen
group were evaluable, respectively. Table 1 shows the pa-
tient backgrounds. As shown in this table, there was no sig-
nificant difference in age or relative dose intensity between
the groups, but there was significant difference in sex, regi-
men, and type of histology.
Antiemetic effects
Figure 1 shows the CR rates for the overall phase, acute
phase, and delayed phase within the evaluation period.
There were no significant differences in CR rate in the
overall phase (80.0 vs. 83.3%, p = 1.000), acute phase
(93.3 vs. 87.5%, p = 1.000), or delayed phase (80.0 vs.
87.5%, p = 0.658) between the aprepitant and control
regimen groups. Figure 2 shows the CP rates for overall
phase, acute phase, and delayed phase within the evalu-
ation period. In the aprepitant and control regimen
groups, there was no significant difference in CP rate in
overall phase (80.0 vs. 79.2%, p = 1.000), acute phase
(93.3 vs. 87.5%, p = 1.000), and delayed phase (80.0 vs.
83.3%, p = 1.000). The time to first vomiting and using
rescue medication is shown in Fig. 3. Again, the two
groups did not show a statistically significant difference
in this variable (p = 0.909).
Discussion
In this study, we compared antiemetic effect with grani-
setron and aprepitant combined with granisetron at the
time of CHOP or R-CHOP regimen. We found no sig-
nificant difference in CR rate, CP rate, or time to first
onset of vomiting and using rescue medication in the
evaluation period. CR rate and CP rate exceeded ap-
proximately 80% in the acute, delayed, and overall
phases. These results suggest that granisetron only could
be one treatment option in patients with non-Hodgkin
lymphoma who have received CHOP or R-CHOP regi-
men. In a previous study, Takahashi et al. performed a
retrospective study to evaluate the effects of oral and
intravenous first-generation 5-HT3 receptor antagonists
(ondansetron) in patients with non-Hodgkin lymphoma
who received R-CHOP or CHOP regimen [9]. They re-
ported that the CR rate did not differ between the two
groups (overall: 82.1% vs. 78.8%, p = 0.77; acute phase:
87.2% vs. 90.9%, p = 0.72; delayed phase: 84.6% vs. 81.8%,
p = 0.76), suggesting that ramosetron is one of the opti-
mal options for preventing CINV in patients treated
with CHOP or R-CHOP regimen. The use of the first-
generation 5-HT3 antagonist for the MEC regimen, in-
cluding AC therapy, which does not contain large
amounts of steroids, unlike the CHOP regimen, has been
reported with a CR rate of 69% in the acute phase and
49% in the delayed phase [10]. Our results included a
higher rate of acute CR (93.3%) than in that previous re-
port. This discrepancy appears to be largely due to the
antiemetic effect caused by the use of a high dose of
prednisolone. Oral administration of prednisolone to
days 4 to 5 of the CHOP regimen may reduce or delay
vomiting, even without aprepitant.
Morita et al. performed a prospective study to evaluate
the efficacy of aprepitant for patients with non-Hodgkin
Table 1 Patient backgrounds treated with CHOP or R-CHOP regimen in malignant lymphoma with or without aprepitant
Total Aprepitant regimen group Control regimen group p value
No. of patients 39 15 24
Age
Median (range) 60 (37–75) 67 (27–76) 0.71
< 50 years 6 2 4 0.063
> 50 years 33 13 20
Sex
Male 19 6 13 0.042
Female 20 9 11
R-CHOP 25 8 17 0.029
CHOP 14 7 7
Type of histology
FL 6 3 3 0.049
DLBCL 22 7 15 0.036
Othera 11 5 6 0.053
RDI of CHOP (%) 94 91 0.33
Statistical analyses were performed with the Chi-squared test
(%) Relative dose intensity (RDI) = dose intensity (mg/m2/week)/planned dose intensity (mg/m2/week) × 100
Abbreviations: R-CHOP Rituximab, cyclophosphamide, doxorubicin, vincristine, prednisolone, CHOP Cyclophosphamide, doxorubicin, vincristine, predonisolone, FL
Follicular lymphoma, DLBCL Diffuse large B-cell lymphoma
aPTCL, peripheral T cell lymphoma; ALCL, anaplastic large cell lymphoma, AITL, angioimmunoblastic T cell lymphoma; IVL, intravascular lymphoma
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lymphoma who experienced nausea, vomiting, or an-
orexia exceeding grade 1 in the first course of CHOP
regimen and who received aprepitant for 3 days in
addition to granisetron with the second course. With the
second course, the number and severity of CINV epi-
sodes decreased compared with those in the first course.
Nausea and anorexia were also significantly reduced
(p < 0.05) [11]. The authors reported that the addition of
aprepitant to 5-HT3 receptor antagonist appears to be
effective for CINV or anorexia in patients who have re-
ceived CHOP regimen. However, they only reported an
analysis of the effect of aprepitant on patients in whom
granisetron treatment as an antiemetic therapy had
failed. Therefore, it is unknown which is better: granise-
tron or aprepitant + granisetron for CHOP during the first
regimen. Zeng et al. also performed a prospective investi-
gation of the efficacy and safety of triple therapy with
aprepitant, ondansetron, and prednisolone in patients with
non-Hodgkin lymphoma receiving rituximab + cyclophos-
phamide + epirubicin + vincristine + prednisolone (R-
CEOP) or CEOP regimen [12]. They concluded that the
CR rate upon triple therapy was statistically superior to
the double therapy (ondansetron and prednisolone) in the
overall observation period (76.5% vs. 56.0%; p = 0.03).
However, no comparison of the emetogenic intensity be-
tween CHOP and CEOP has been performed; it is not
possible to conclude that aprepitant+first-generation 5-
HT3 antagonist are superior to the first-generation 5-HT3
antagonist in preventing CHOP regimen-induced acute
and delayed emesis.
Because aprepitant has CYP3A4 inhibitory activity, atten-
tion must be paid to drug interaction when it is used in
combination with CYP3A4 substrates. It has been reported
that the frequency of occurrence of chemotherapy-induced
peripheral neuropathy due to vincristine, a CYP3A4 sub-
strate, increased when aprepitant was used in combination
with the CHOP regimen, and it is possible that aprepitant
may contribute to an increase of vincristine-induced side
effects [13]. Considering that high antiemetic rates can be
expected without using aprepitant and that vincristine
interact with CYP3A4, aprepitant might not be needed in
patients with non-Hodgkin lymphoma receiving CHOP or
R-CHOP regimen. In the present study, the frequency of
peripheral neuropathy was no significant difference be-
tween the aprepitant regimen group and the control during
the first course (7.1% vs 5.0%; p = 0.11).
However this our exploratory analysis focus on short-
term peripheral neuropathy. Therefore, further long-term,
prospective studies are needed to assess chemotherapy-
induced peripheral neuropathy in patients undergoing
treatment with CHOP or R-CHOP regimen in combin-
ation with aprepitant.
This study had some limitations, such as its retro-
spective nature and inclusion of a small number of pa-
tients from a heterogeneous population. Additionally,
the presented study only evaluated the period of 0–120 h
during the first cycle. A previous study reported that
several patients experienced vomiting during 120–168 h
after CHOP chemotherapy [14].
Fig. 2 Complete protection rate during the overall (0–120 h), acute
(0–24 h), and delayed (24–120 h) phases. For the aprepitant regimen:
n = 15. For the control regimen n = 24. p = 1.000, 1.000, 1.000 versus
control regimen
Fig. 3 Time to first vomiting and using rescue medication during
the overall (0–120 h) phases. The two groups did not show a
statistically significant difference in this variable (p = 0.909)
Fig. 1 Complete response rate during the overall (0–120 h), acute
(0–24 h), and delayed (24–120 h) phases. For the aprepitant regimen:
n = 15. For the control regimen n = 24. p = 1.000, 1.000, 0.658 versus
control regimen
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In the present study, there are significant differences in the
number of female patients between the aprepitant regimen
group and the control regimen group. Female is reported to
be a risk factor of emesis induced by chemotherapy [15]. In
the present study, no difference between granisetron plus
aprepitant and granisetron was observed in CR or CP in fe-
male patients with treated CHOP or R-CHOP regimen (CR:
77.8% vs 72.7%; p = 1.00; CP: 77.8% vs 81.8%; p = 1.00). Al-
though not significant, granisetron plus aprepitant tend to be
high CR for female patient receiving CHOP or R-CHOP
regimen. Recently, Yoshida et al. reported that female gender
and young age were risk factors for early-phase nausea, while
female gender remained a risk factor for late-phase CINV in
patients with haematological malignancies. They also re-
ported that CR and complete control were, not significantly,
increased by 8.6 and 13.9%, respectively, in patients receiving
triple antiemetics (aprepitant+ 5-HT3 receptor antagonist
+dexamethasone) in CHOP-like regimens, compared to
those with double antiemetics (5-HT3 receptor antagonist
+dexamethasone) [16]. Considering the result of above study,
aprepitant might be considered for HEC, especially in young
female with non-Hodgkin lymphoma receiving CHOP or R-
CHOP. However, owing to the small number of patients en-
rolled in the study and the exploratory nature of the analysis,
no conclusions could be drawn. Therefore, further large-
scale, prospective studies are necessary to appropriately pre-
vent CINV in those undergoing treatment with CHOP
regimen.
Conclusion
The results of this study suggest that granisetron alone
could be one treatment option in the management of
CINV in patients with non-Hodgkin lymphoma receiv-
ing CHOP or R-CHOP regimen. However, this study





YW, SN,YI, MH and TT contributed equally to planning the study design and
drafting the manuscript; KK and HM made substantial contributions to data
analysis. All authors read and approved the final manuscript.
Funding
Not applicable.
Availability of data and materials
The datasets generated and/or analyzed during the current study are not
publicly available because transfer of data containing personal information
outside Shiga University of Medical Science Hospital is not allowed.
Ethics approval and consent to participate
The present study was approved by the ethics committee of Shiga University
of Medicine (approval number: 28–27). No consent was obtained from





The authors declare that they have no competing interests.
Author details
1Department of Pharmacy, Shiga University of Medical Science Hospital,
520-2192 Seta Tsukinowa-cho, Otsu-shi, Shiga, Japan. 2Department of
Hematology, Shiga University of Medical Science Hospital, 520-2192 Seta
Tsukinowa-cho, Otsu-shi, Shiga, Japan.
Received: 7 August 2019 Accepted: 30 October 2019
References
1. Ballatori E, Roila F, et al. Impact of nausea and vomiting on quality of life in
cancer patients during chemotherapy. Health Qual Life Outcomes. 2003;1:46.
2. Grunberg SM, Boutin N, et al. Impact of nausea/vomiting on quality of life
as a visual analogue scale-derived utility score. Support Care Cancer. 1996;
4(6):435–9.
3. Hesketh PJ, Kris MG, et al. Antiemetics: American Society of Clinical Oncology
clinical practice guideline update. J Clin Oncol. 2017;35(28):3240–61.
4. Coiffier B, Lepage E, et al. CHOP chemotherapy plus rituximab compared
with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N
Engl J Med. 2002;346(4):235–42.
5. Japan Society of Clinical Oncology. Guidelines for appropriate use of
antiemetic drugs (version 2.2, 2015). Available at http://jsco-cpg.jp/item/29/
index.html. Accessed 12 Mar 2019.
6. National Comprehensive Cancer Network. Clinical practice guidelines in
oncology: Antiemesis (Ver1, 2019). Available at https://www.nccn.org/
professionals/physician_gls/pdf/antiemesis.pdf. Accessed 12 Mar 2019.
7. MASCC/ESMO Antiemesis Guidline 2016. Available at https://www.mascc.
org/asset/Guidlines-Tools/mascc_antiemetic_guidlines_establish_2016_v.1.2.
pdf. Accessed 12 Mar 2019.
8. Tamura K, Aiba K, et al. Testing the effectiveness of antiemetic guidelines:
results of a prospective registry by the CINV study Group of Japan. Int J Clin
Oncol. 2015;20(5):855–65.
9. Takahashi T, Kumanomidou S, et al. A retrospective study of R-CHOP/CHOP
therapy-induced nausea and vomiting in non-Hodgkin's lymphoma
patients: a comparison of intravenous and oral 5-HT3 receptor antagonists.
Int J Hematol. 2016;104(3):378–83.
10. Warr DG, Hesketh PJ, et al. Efficacy and tolerability of aprepitant for the
prevention of chemotherapy-induced nausea and vomiting in patients with
breast cancer after moderately emetogenic chemotherapy. J Clin Oncol.
2005;23(12):2822–30.
11. Morita M, Kishi S, et al. Efficacy of aprepitant for CHOP chemotherapy-induced
nausea, vomiting, and anorexia. Curr Probl Cancer. 2017;41(6):419–25.
12. Song Z, Wang H, et al. Efficacy and safety of triple therapy with aprepitant,
ondansetron, and prednisone for preventing nausea and vomiting induced
by R-CEOP or CEOP chemotherapy regimen for non-Hodgkin lymphoma: a
phase 2 open-label, randomized comparative trial. Leuk Lymphoma. 2017;
58(4):816–21.
13. Okada N, Hanafusa T, et al. Risk factors for early-onset peripheral neuropathy
caused by vincristine in patients with a first administration of R-CHOP or R-
CHOP-like chemotherapy. J Clin Med Res. 2014;6(4):252–60.
14. Miyata Y, Yakushijin K, et al. A prospective study of the antiemetic effect of
palonosetron in malignant lymphoma patients treated with the CHOP
regimen. Int J Hematol. 2016;104(6):682–91.
15. Warr D, et al. Prognostic factors for chemotherapy induced nausea and
vomiting. Eur J Pharmacol. 2014;722:192–6.
16. Yoshida I, Tamura K, et al. Prophylactic Antiemetics for Haematological
malignancies: prospective Nationwide survey subset analysis in Japan. In
Vivo. 2019;33(4):1355–62.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in
published maps and institutional affiliations.
Wakasugi et al. Journal of Pharmaceutical Health Care and Sciences            (2019) 5:24 Page 5 of 5
